EUVIMEDEUVIMED entdecken
Crossref

β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin

Giuseppe Daniele iD, Andrea Tura iD, Alex Brocchi, Alessandro Saba, Beatrice Campi, Veronica Sancho-Bornez, Angela Dardano iD, Stefano Del Prato iD

Diabetes Care · 2024

DOI: 10.2337/dc23-2051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2024. Verfasst von Giuseppe Daniele und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Glucosides, Diabetes Mellitus, Type 2, Adamantane, Benzhydryl Compounds. Die Arbeit nennt 28 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To explore the complementary effects of a combination of dipeptidyl peptidase 4 and sodium–glucose cotransporter 2 inhibitors added to metformin on hormonal and metabolic responses to meal ingestion. RESEARCH DESIGN AND METHODS Forty-five patients (age 58 ± 8 years; HbA1c 58 ± 6 mmol/mol; BMI 30.7 ± 3.2 kg/m2) with type 2 diabetes uncontrolled with metformin were evaluated at baseline and 3 and 28 days after 5 mg saxagliptin (SAXA), 10 mg dapagliflozin (DAPA), or 5 mg saxagliptin plus 10 mg dapagliflozin (SAXA+DAPA) using a mixed-meal tolerance test (MMTT) spiked with dual-tracer glucose to assess glucose metabolism, insulin secretion, and sensitivity. RESULTS At day 3, fasting and mean MMTT glucose levels were lower with SAXA+DAPA (−31.1 ± 1.6 and −91.5 ± 12.4 mg/dL) than with SAXA (−7.1 ± 2.1 and −53 ± 10.5 mg/dL) or DAPA (−17.0 ± 1.1 and −42.6 ± 10.0 mg/dL, respectively; P < 0.001). Insulin secretion rate (SAXA+DAPA +75%; SAXA +11%; DAPA +3%) and insulin sensitivity (+2.2 ± 1.7, +0.4 ± 0.7, and +0.4 ± 0.4 mg ⋅ kg−1⋅ min−1, respectively) improved with SAXA+DAPA (P < 0.007). Mean glucagon-like peptide 1 (GLP-1) was higher with SAXA+DAPA than with SAXA or DAPA. Fasting glucagon increased with DAPA and SAXA+DAPA but not with SAXA. Fasting endogenous glucose production (EGP) increased with SAXA+DAPA and DAPA. During MMTT, EGP suppression was greater (48%) with SAXA+DAPA (vs. SAXA 44%; P = 0.02 or DAPA 34%; P = 0.2). Metabolic clearance rate of glucose (MCRglu) increased more with SAXA+DAPA. At week 4, insulin secretion rate, β-cell glucose sensitivity, and insulin sensitivity had further increased in the SAXA+DAPA group (P = 0.02), with no additional changes in GLP-1, glucagon, fasting or MMTT EGP, or MCRglu. CONCLUSIONS SAXA+DAPA provided superior glycemic control compared with DAPA or SAXA, with improved β-cell function, insulin sensitivity, GLP-1 availability, and glucose clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesDiabetes Mellitus, Type 2AdamantaneBenzhydryl CompoundsInsulin-Secreting CellsIncretinsDipeptidesBlood GlucoseHumansMiddle AgedMaleFemaleAgedHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 Inhibitors

Substanzen

dapagliflozinsaxagliptinGlucosidesAdamantaneBenzhydryl CompoundsIncretinsDipeptidesBlood GlucoseHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Section of Metabolic Diseases and Diabetes, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Metabolic Unit, Consiglio Nazionale delle Ricerche Institute of Neuroscience, Padova, Italy.
  • Department of Surgical, Medical, Molecular, and Critical Care Pathology, University of Pisa, Pisa, Italy.
  • Interdisciplinary Research Center for Health Science, Sant'Anna School of Advanced Studies, Pisa, Italy.

ORCID-Profile: Giuseppe Daniele, Andrea Tura, Angela Dardano, Stefano Del Prato

Förderung

  • AstraZeneca

Zitieren

APA

Daniele, G., Tura, A., Brocchi, A., Saba, A., Campi, B., Sancho-Bornez, V., Dardano, A., & Del Prato, S. (2024). β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care. https://doi.org/10.2337/dc23-2051

Vancouver

Daniele G, Tura A, Brocchi A, Saba A, Campi B, Sancho-Bornez V, et al. β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. Diabetes Care. 2024. doi:10.2337/dc23-2051

BibTeX
@article{Daniele2024,
  author = {Daniele, Giuseppe and Tura, Andrea and Brocchi, Alex and Saba, Alessandro and Campi, Beatrice and Sancho-Bornez, Veronica and Dardano, Angela and Del Prato, Stefano},
  title = {β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin},
  journal = {Diabetes Care},
  year = {2024},
  doi = {10.2337/dc23-2051}
}
Kostenlos starten →